Table 1 Correlation between the serum GAL3BP level with SIGLEC14 genotype and the clinicopathological characteristics of CRC patients
| Â | Case No. | LGALS3BP high | LGALS3BP low | p value |
|---|---|---|---|---|
|  | N = 357 | N = 73 | N = 284 |  |
Age | ||||
 ≥65 | 170 | 29 | 141 | 0.1489 |
 <65 | 187 | 44 | 143 |  |
Gender | ||||
 Male | 191 | 34 | 157 | 0.191 |
 Female | 166 | 39 | 127 |  |
T stage | ||||
 T1-T2 | 37 | 7 | 30 | >0.9999 |
 T3-T4 | 320 | 66 | 254 |  |
N stage | ||||
 N0 | 177 | 24 | 153 | 0.0058 |
 N1 | 115 | 32 | 83 |  |
 N2 | 65 | 17 | 48 |  |
M stage | ||||
 M0 | 342 | 65 | 277 | 0.0037 |
 M1 | 15 | 8 | 7 |  |
Differentiation | ||||
 Poor | 32 | 6 | 26 | 0.8725 |
 Moderate | 323 | 67 | 256 |  |
 Well | 1 | 0 | 1 |  |
Location | ||||
 Right colon | 139 | 24 | 115 | 0.3547 |
 Left colon | 169 | 40 | 129 |  |
 Rectal | 49 | 9 | 40 |  |
CEA (ng/ml) | ||||
 > 5 | 146 | 33 | 113 | 0.425 |
 ≤ 5 | 211 | 40 | 171 |  |
CA19-9 (U/ml) | ||||
 >37 | 54 | 12 | 42 | 0.7162 |
 ≤37 | 303 | 61 | 242 |  |
MSI | ||||
 MSI-H | 28 | 0 | 38 | 0.0002 |
 MSS | 273 | 65 | 208 |  |
Immune cell infiltration | ||||
 Positive | 141 | 16 | 125 | 0.0005 |
 Negative | 216 | 57 | 159 |  |
Vascular invasion | ||||
 Positive | 99 | 27 | 72 | 0.0572 |
 Negative | 257 | 46 | 211 |  |
Lymphatic invasion | ||||
 Positive | 106 | 30 | 76 | 0.0213 |
 Negative | 251 | 43 | 208 |  |
SIGLEC14 | ||||
 Positive | 227 | 55 | 172 | 0.0205 |
 Negative | 130 | 18 | 112 |  |
